Biopharmaceutical News and Research

RSS

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have entered into an agreement regarding the development, commercialization and manufacturing of Immutep’s ImmuFact IMP321.

7 Oct 2013

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

7 Oct 2013

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that a Services Agreement has been signed with the German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS) whereby GRCBDS will provide pharmaceutical development and GMP manufacturing services for Kiadis Pharma's ongoing Phase II clinical study with ATIR™.

7 Oct 2013

EMD Serono announces recipients of company's inaugural Grant for Multiple Sclerosis Innovation

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today on the occasion of the 29th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the recipients of the company's inaugural Grant for Multiple Sclerosis Innovation (GMSI).

7 Oct 2013

Researchers discover way to use stem cells as drug delivery vehicles

A group of Brigham and Women's Hospital, and Harvard Stem Cell Institute researchers and collaborators at MIT and MGH have found a way to use stem cells as drug delivery vehicles.

5 Oct 2013

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.

3 Oct 2013

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.

1 Oct 2013

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment (Grass-Synthetic Peptide Immuno-Regulatory Epitope [Grass-SPIRE])

1 Oct 2013

Merck Canada Gives Patient-Oriented Research $4M Boost

...

30 Sep 2013

Amgen Plans R&D Center In China

...

25 Sep 2013

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.

24 Sep 2013

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

Packaging Coordinators, Inc. (PCI), a global supplier of pharmaceutical commercial packaging solutions and clinical trials services is pleased to announce that it will be exhibiting its full range of services on booth 41M15 at CPhI Worldwide. Exhibiting for the first time as Packaging Coordinators, inc. since May 2013 when AndersonBrecon merged with and operated as Frazier Healthcare’s portfolio company, PCI, the company is now one of the largest suppliers of packaging supply services to the pharmaceutical industry and will be demonstrating its capabilities in clinical trials, in laboratory services and commercial services for pharmaceutical and biopharmaceutical customers.

From Packaging Coordinators Inc. (PCI) 23 Sep 2013

Study sheds light on investment levels across 12 key marketing, education and payer activities

In order for a new product to gain a foothold in today's competitive pharmaceutical market, executives must understand where and when to invest in key launch activities. At the same time, product launch leaders have to balance the goals of containing expenditures and generating a successful launch.

21 Sep 2013

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

Ventana Medical Systems, Inc., a member of the Roche Group, and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

19 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.

17 Sep 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).

16 Sep 2013

Biopharmaceutical News and Research

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

EMD Serono announces recipients of company's inaugural Grant for Multiple Sclerosis Innovation

Researchers discover way to use stem cells as drug delivery vehicles

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Merck Canada Gives Patient-Oriented Research $4M Boost

Amgen Plans R&D Center In China

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

Study sheds light on investment levels across 12 key marketing, education and payer activities

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

How to optimize your cell line development eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News